1-6 of 6
Nahla Hasabou
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Timing of Response with Gilteritinib Monotherapy in Relapsed or Refractory FLT3 -Mutated Acute Myeloid Leukemia

Alexander E. Perl, Mark J. Levis, Andrew Wei, Hee-je Kim, June-won Cheong, Yu Zhang, Jian Li, Hisayuki Yokoyama, Naoko Hosono, Nahla Hasabou, Dina Elsouda, Jamie Jung-Hee An, Jianxiang Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 2889.
https://doi.org/10.1182/blood-2024-204831
Published: 2024
Journal Articles

Post-Hoc Analysis of Measurable Residual Disease from BMT-CTN 1506/Morpho: FLT3-ITD Variant Allele Frequency and Survival Are Highly Correlated

Mark J. Levis, Mehdi Hamadani, Brent R. Logan, Richard J. Jones, Anurag K. Singh, Mark R. Litzow, John R. Wingard, Esperanza B. Papadopoulos, Alexander Perl, Robert J. Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K. Waller, Sumithira Vasu, Melhem M. Solh, Asmita Mishra, Lori S. Muffly, Hee-Je Kim, Matthias Stelljes, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H. Wei, Guido Marcucci, Nahla Hasabou, Mathew Rosales, Jason Hill, Stanley C. Gill, Rishita Nuthethi, Denise King, Heather Wittsack, Adam Mendizabel, Steven M. Devine, Mary M. Horowitz, Yi-Bin Chen
Journal: Blood
Blood (2023) 142 (Supplement 1): 973.
https://doi.org/10.1182/blood-2023-177929
Published: 2023
Journal Articles

Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

Clinical Trials & Observations
Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Ehab Atallah, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Récher, Sung-Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee-Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramon Tiu, Mark J. Levis
Journal: Blood
Blood (2022) 139 (23): 3366–3375.
https://doi.org/10.1182/blood.2021011583
Published: 2022
Includes: Supplemental data
Journal Articles

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Jianxiang Wang, Bin Jiang, Jian Li, Ligen Liu, Xin Du, Hao Jiang, Jianda Hu, Menghe Yuan, Taishi Sakatani, Takeshi Kadokura, Masato Takeuchi, Shunsuke Izuka, Larisa Girshova, Jerome Tan, Sergey N. Bondarenko, Lily LL Wong, Archrob Khuhapinant, Elena Martynova, Nahla Hasabou, Ramon V. Tiu
Journal: Blood
Blood (2021) 138 (Supplement 1): 695.
https://doi.org/10.1182/blood-2021-145436
Published: 2021
Journal Articles

Clinical Outcomes Following Treatment with Gilteritinib or Quizartinib in Patients with Relapsed/Refractory FLT3 -ITD+ Acute Myeloid Leukemia

Alexander E. Perl, MD, Qiaoyang Lu, MS, Alan Fan, MS Pharm, Nahla Hasabou, MD, Erhan Berrak, MD, Ramon V. Tiu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
https://doi.org/10.1182/blood-2020-136118
Published: 2020
Journal Articles

Clinical Outcomes in Patients with Relapsed/Refractory Acute Myeloid Leukemia Treated with Gilteritinib Who Received Prior Midostaurin or Sorafenib

Alexander E. Perl, MD, Jessica K. Altman, MD, Naoko Hosono, MD PhD, Pau Montesinos, MD PhD, Nikolai A. Podoltsev, MD PhD, Giovanni Martinelli, MD, Catherine C. Smith, MD, Mark Levis, MD PhD, Christoph Röllig, Prof., MD, Marco Groß-Langenhoff, PhD, Nahla Hasabou, MD, Qiaoyang Lu, MS, Ramon V. Tiu, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-136395
Published: 2020